<div id="readability-page-1"><ul><li>3 Companies at the Forefront of the GLP-1 Pill Wars</li></ul><p>Eli Lilly and Company, AbbVie, Abbott Laboratories, Pfizer, Gilead Sciences, Bristol Myers Squibb,  and Vertex Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and related therapies. Investors in these stocks watch drug pipelines, regulatory approvals, patent protection, pricing/reimbursement, and clinical trial results, because those factors can drive significant volatility and long‑term value changes. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>3 Stocks That Could Be Next to Announce a Stock Split</li></ul><p>Read Our Latest Research Report on LLY</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><ul><li>Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand</li></ul><p>Read Our Latest Research Report on ABBV</p><h2>Abbott Laboratories (ABT)</h2><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><p>Read Our Latest Research Report on ABT</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Gilead Sciences (GILD)</h2><p>Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p><p>Read Our Latest Research Report on GILD</p><h2>Bristol Myers Squibb (BMY)</h2><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><p>Read Our Latest Research Report on BMY</p><h2>Vertex Pharmaceuticals (VRTX)</h2><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><p>Read Our Latest Research Report on VRTX</p><h2>See Also</h2><ul><li>MarketBeat's Top Five Stocks to Own in March 2026</li><li>DICK’S Sporting Goods Could Be Ready for Another Breakout</li><li>Home Depot Stock Keeps Falling—Analysts Say the Upside Is Still There</li><li>Avoid the Top-Heavy S&amp;P 500 With Equal-Weight ETFs</li><li>Why Mastercard and Visa Are the Definition of Forever Stocks</li><li>Amazon Is Rising While the Market Falls—Here’s Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GILD

LLYX

<p>Eli Lilly, AbbVie, Abbott Laboratories, Pfizer, Gilead Sciences, Bristol Myers Squibb, and Vertex Pharmaceuticals are the top pharmaceutical stocks to watch today, as identified by MarketBeat's stock screener. These companies are notable for their significant trading volumes and are involved in the research, development, and sale of prescription drugs. Investors monitor various factors such as drug pipelines and regulatory approvals that can impact stock volatility and long-term value.</p>

- Eli Lilly and Company, AbbVie, Abbott Laboratories, Pfizer, Gilead Sciences, Bristol Myers Squibb, and Vertex Pharmaceuticals are highlighted as top pharmaceutical stocks by MarketBeat.  
- These companies are involved in various treatments ranging from diabetes and cancer to infectious diseases, with significant trading volume observed recently.  
- Investors are advised to monitor these stocks due to their volatile nature influenced by drug pipelines, regulatory approvals, and clinical trial results.

Top Pharmaceutical Stocks To Watch Today - March 14th